-
Posted by
Two Blokes Jun 11 -
Filed in
Stock
-
6 views
Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e-commerce and pharma-grade injectables, with operating leverage and efficient marketing boosting profitability. Valuation is rich, reflecting high expectations for continued growth and clinical pipeline success, but execution risk is elevated at these multiples.
